Cargando…

Comparison of a Novel Bisphosphonate Prodrug and Zoledronic Acid in the Induction of Cytotoxicity in Human Vγ2Vδ2 T Cells

Increasing attention has been paid to human γδ T cells expressing Vγ2Vδ2 T cell receptor (also termed Vγ9Vδ2) in the field of cancer immunotherapy. We have previously demonstrated that a novel bisphosphonate prodrug, tetrakis-pivaloyloxymethyl 2-(thiazole-2-ylamino)ethylidene-1,1-bisphosphonate (PTA...

Descripción completa

Detalles Bibliográficos
Autores principales:	Okuno, Daisuke, Sugiura, Yuki, Sakamoto, Noriho, Tagod, Mohammed S. O., Iwasaki, Masashi, Noda, Shuto, Tamura, Akihiro, Senju, Hiroaki, Umeyama, Yasuhiro, Yamaguchi, Hiroyuki, Suematsu, Makoto, Morita, Craig T., Tanaka, Yoshimasa, Mukae, Hiroshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7385076/ https://www.ncbi.nlm.nih.gov/pubmed/32793196 http://dx.doi.org/10.3389/fimmu.2020.01405

Ejemplares similares

Three distinct mechanisms underlying human γδ T cell-mediated cytotoxicity against malignant pleural mesothelioma
por: Umeyama, Yasuhiro, et al.
Publicado: (2023)

Anti-Tumor Activity and Immunotherapeutic Potential of a Bisphosphonate Prodrug
por: Tanaka, Yoshimasa, et al.
Publicado: (2017)

Enhancing adoptive cancer immunotherapy with Vγ2Vδ2 T cells through pulse zoledronate stimulation
por: Nada, Mohanad H., et al.
Publicado: (2017)

CAR-Modified Vγ9Vδ2 T Cells Propagated Using a Novel Bisphosphonate Prodrug for Allogeneic Adoptive Immunotherapy
por: Wang, Yizheng, et al.
Publicado: (2023)

Expansion of human γδ T cells for adoptive immunotherapy using a bisphosphonate prodrug
por: Tanaka, Yoshimasa, et al.
Publicado: (2018)

Two Distinct Mechanisms Underlying γδ T Cell-Mediated Regulation of Collagen Type I in Lung Fibroblasts
por: Okuno, Daisuke, et al.
Publicado: (2022)

Prodrugs of pyrophosphates and bisphosphonates: disguising phosphorus oxyanions
por: Rudge, Emma S., et al.
Publicado: (2022)

Safety and tolerability of zoledronic acid and other bisphosphonates in osteoporosis management
por: Dalle Carbonare, Luca, et al.
Publicado: (2010)

Nanoformulated Zoledronic Acid Boosts the Vδ2 T Cell Immunotherapeutic Potential in Colorectal Cancer
por: Di Mascolo, Daniele, et al.
Publicado: (2019)

Hepatocellular carcinoma cell sensitivity to Vγ9Vδ2 T lymphocyte-mediated killing is increased by zoledronate
por: SUGAI, SHIORI, et al.
Publicado: (2016)

Macrophage Depletion by Free Bisphosphonates and Zoledronate-Loaded Red Blood Cells
por: Sabatino, Raffaella, et al.
Publicado: (2014)

Safety of Intravitreal Zoledronic Acid, an Anti-angiogenic Bisphosphonate, in a Rat Model
por: Nourinia, Ramin, et al.
Publicado: (2014)

Denosumab or Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates
por: Miller, P. D., et al.
Publicado: (2016)

HSP47: A Therapeutic Target in Pulmonary Fibrosis
por: Sakamoto, Noriho, et al.
Publicado: (2023)

The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel
por: Jagdev, S P, et al.
Publicado: (2001)

Platelet-Rich Plasma in Treatment of Zoledronic Acid-Induced Bisphosphonate-related Osteonecrosis of the Jaws
por: Sarkarat, Farzin, et al.
Publicado: (2014)

Geranylgeraniol Restores Zoledronic Acid-Induced Efferocytosis Inhibition in Bisphosphonate-Related Osteonecrosis of the Jaw
por: Chen, Xin, et al.
Publicado: (2021)

The bisphosphonates alendronate and zoledronate induce adaptations of aerobic metabolism in permanent human endothelial cells
por: Budzinska, Adrianna, et al.
Publicado: (2023)

Combining Vγ9Vδ2 T Cells with a Lipophilic Bisphosphonate Efficiently Kills Activated Hepatic Stellate Cells
por: Zhou, Xiaoying, et al.
Publicado: (2017)

Intraperitoneal injection of in vitro expanded Vγ9Vδ2 T cells together with zoledronate for the treatment of malignant ascites due to gastric cancer
por: Wada, Ikuo, et al.
Publicado: (2014)

PD-1 checkpoint blockade enhances adoptive immunotherapy by human Vγ2Vδ2 T cells against human prostate cancer
por: Nada, Mohanad H., et al.
Publicado: (2021)

Aryloxy Diester Phosphonamidate Prodrugs of Phosphoantigens (ProPAgens) as Potent Activators of Vγ9/Vδ2 T-Cell Immune Responses
por: Kadri, Hachemi, et al.
Publicado: (2020)

Zoledronate Triggers Vδ2 T Cells to Destroy and Kill Spheroids of Colon Carcinoma: Quantitative Image Analysis of Three-Dimensional Cultures
por: Varesano, Serena, et al.
Publicado: (2018)

The bisphosphonate zoledronic acid impairs membrane localisation and induces cytochrome c release in breast cancer cells
por: Senaratne, S G, et al.
Publicado: (2002)

The bisphosphonate zoledronic acid impairs membrane localisation and induces cytochrome c release in breast cancer cells
por: Senaratne, S G, et al.
Publicado: (2002)

Zoledronate treatment duration is linked to bisphosphonate‐related osteonecrosis of the jaw prevalence in rice rats with generalized periodontitis
por: Messer, Jonathan G., et al.
Publicado: (2019)

Corrigendum: Zoledronate Triggers Vδ2 T Cells to Destroy and Kill Spheroids of Colon Carcinoma: Quantitative Image Analysis of Three-Dimensional Cultures
por: Varesano, Serena, et al.
Publicado: (2018)

Vδ2 T cells are associated with favorable clinical outcomes in patients with bladder cancer and their tumor reactivity can be boosted by BCG and zoledronate treatments
por: Nguyen, Sylvain, et al.
Publicado: (2022)

Bacillus Calmette-Guerin (BCG) induces superior anti-tumour responses by Vδ2(+) T cells compared with the aminobisphosphonate drug zoledronic acid
por: Fenn, J, et al.
Publicado: (2022)

Combined effects of a third-generation bisphosphonate, zoledronic acid with other anticancer agents against murine osteosarcoma
por: Horie, N, et al.
Publicado: (2007)

Novel SPEF2 Variant in a Japanese Patient with Primary Ciliary Dyskinesia: A Case Report and Literature Review
por: Mori, Mayako, et al.
Publicado: (2022)

Adjunctive Zoledronate + IL-2 administrations enhance anti-tuberculosis Vγ2Vδ2 T-effector populations, and improve treatment outcome of multidrug-resistant tuberculosis(1)
por: Shen, Hongbo, et al.
Publicado: (2022)

Dabrafenib and trametinib therapy in an elderly patient with non‐small cell lung cancer harboring the BRAF V600E mutation
por: Dotsu, Yosuke, et al.
Publicado: (2020)

New insights into the actions of bisphosphonate zoledronic acid in breast cancer cells by dual RhoA-dependent and -independent effects
por: Denoyelle, C, et al.
Publicado: (2003)

Combined effects of the bisphosphonate, zoledronic acid and the aromatase inhibitor letrozole on breast cancer cells in vitro: evidence of synergistic interaction
por: Neville-Webbe, H L, et al.
Publicado: (2010)

Bone targeting compounds for radiotherapy and imaging: *Me(III)-DOTA conjugates of bisphosphonic acid, pamidronic acid and zoledronic acid
por: Meckel, M., et al.
Publicado: (2016)

Adoptive transfer of zoledronate-expanded autologous Vγ9Vδ2 T-cells in patients with treatment-refractory non-small-cell lung cancer: a multicenter, open-label, single-arm, phase 2 study
por: Kakimi, Kazuhiro, et al.
Publicado: (2020)

Zoledronic acid renders human M1 and M2 macrophages susceptible to Vδ2(+) γδ T cell cytotoxicity in a perforin-dependent manner
por: Fowler, Daniel W., et al.
Publicado: (2017)

Protocol for a randomised control trial of bisphosphonate (zoledronic acid) treatment in childhood femoral head avascular necrosis due to Perthes disease
por: Jamil, Kamal, et al.
Publicado: (2017)

Priming of Colorectal Tumor-Associated Fibroblasts with Zoledronic Acid Conjugated to the Anti-Epidermal Growth Factor Receptor Antibody Cetuximab Elicits Anti-Tumor Vδ2 T Lymphocytes
por: Fernandez, Jordi Leonardo Castrillo, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_nesmeol5v2sspcplmnat3911bu